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Abstract
Background: Simultaneous occurrence of exocrine and neuroendocrine tumors of the pancreas is very infrequent.
We report a patient with an endocrine tumor in the pancreatic-duodenal area and extensive exocrine carcinoma
involving the whole pancreas.
Case presentation: A 69-year-old woman was hospitalized in May 2016 for epigastric pain and weight loss. Her past
medical history revealed an undefined main pancreatic duct dilation that was subsequently confirmed at CT scan
(23 mm) and endoscopic ultrasound. There was no evidence of pancreatic masses, but the cephalic portion of the
main pancreatic duct presented hypoechoic nodules. A diagnosis of the main-duct intraductal papillary mucinous
neoplasm was made, and the patient underwent total pancreatectomy. Pathological examination showed a collision
tumor constituted by a ductal adenocarcinoma involving the whole pancreas and a neuroendocrine tumor located in
the duodenal peripancreatic wall and the head of the pancreas. There was one peripancreatic lymph node metastasis
from the ductal adenocarcinoma and eight node metastases from the neuroendocrine tumor. These findings
suggested a diagnosis of collision of neuroendocrine and ductal adenocarcinomas of the pancreas. The postoperative
course was uneventful.
Conclusions: The coexistence of pancreatic endocrine and exocrine tumors is very uncommon. When present,
problems in differential diagnosis may arise between mixed exocrine-endocrine carcinoma or the collision of separate
tumors.
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Background
Simultaneous occurrence of a pancreatic exocrine and
endocrine tumor (neuroendocrine tumor (NET)) is very
infrequent. In large series studies, the incidence of com-
bined neoplasms ranged only from 0.06 to 0.2% of all pan-
creatic tumors [1, 2]. Collision cancers are defined as
tumors located in the same organ or anatomic site. Ac-
cording to the World Health Organization (WHO) histo-
logical classification, collision tumors include at least two
different malignant components, without mixed or transi-
tional area [3]. In this study, we report a patient with a
collision pancreatic tumor constituted by a pancreatic
ductal adenocarcinoma (PDAC) and NET associated with
a jejunal gastrointestinal stromal tumor (GIST). A review
of the English literature was performed searching PubMed
(MEDLINE) using “pancreatic neoplasms,” “pancreatic
cancer,” “neuroendocrine tumor,” and “pancreatic collision
tumor” as keywords. The related article function was used,
and all abstracts, studies, and citations obtained were
reviewed. To our knowledge, this is the first case of an ex-
tensive PDAC that collided with a NET.
Case presentation
A 68-year-old Caucasian woman was admitted in May
2016 for the examination of a suspected intraductal pap-
illary mucinous neoplasm (IPMN). Her previous medical
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history included breast cancer, diabetes mellitus, hyper-
tension, hypercholesterolemia, and multiple congenital
skeletal dysplasia. She presented with weight loss, epi-
gastric pain, and fatigue. Laboratory examination re-
vealed high carbohydrate antigen 19-9 (Ca 19-9) serum
levels (139.9 U/mL; normal value <37 U/mL). Triple-
phase computed tomography (CT) of the abdomen de-
tected a dilated main duct (diameter of 23 mm from the
head to the tail) without solid lesions (Fig. 1). Endo-
scopic ultrasound (EUS) confirmed main duct dilatation
>20 mm, with mural hypoechoic nodules (Fig. 2). Malig-
nant main-duct IPMN was suggested, and the patient
underwent surgery. At laparotomy, neither liver metasta-
sis nor peritoneal seeding were found. A solid 26-mm le-
sion in the jejunal wall was incidentally detected. So,
total pancreatectomy and excision of the jejunal lesion
were performed. The postoperative period was
uneventful.
Macroscopic examination of the resected specimen
showed a dilated main pancreatic duct (diameter of
20 mm for a length of 80 mm); an irregular, not well-
defined mass (50 mm in longest diameter) in the body-
tail of the pancreas; and a solid lesion in the jejunum.
Microscopic sections showed a collision pancreatic
tumor constituted by a ductal adenocarcinoma, includ-
ing pancreatic intraepithelial neoplasia (PanIN), and a
G1 NET, in the duodenal peripancreatic wall and the
head of the pancreas (Fig. 3). The PDAC collided with
the NET without mixing: the NET was localized in the
periduodenal portion of the head of the pancreas reach-
ing also the duodenal wall nearby Vater’s ampulla, while
the exocrine component of the tumor involved the
remaining pancreas, from the head to the tail. Lympho-
vascular invasion and perineural spreading were also de-
tected. Thirty-nine regional lymph nodes were examined
in the resected specimen with one node metastasis (peri-
pancreatic node) from the PDAC and eight node
metastases from the NET (seven peripancreatic nodes
and one para-aortic node). The ductal differentiation
was of conventional type, characterized by medium-
sized glandular structures of variable shapes, embedded
in desmoplastic stroma with foci of poor glandular dif-
ferentiation found in the peripancreatic tissue. The neo-
plastic glands infiltrated the underlying duodenum. The
endocrine component grew up in the head of the pan-
creas and in the duodenal wall reaching the submucosa,
with signs of endo-lymphatic invasion. At immunohisto-
chemistry analysis, endocrine cells were synaptophysin+
(Fig. 4), chromogranin A+ (Fig. 5), NSE +, and somato-
statin+ (weakly) and showed a mitotic index of 1–2 mi-
toses × 10 HPF, a Ki-67 proliferation index of 2%, and
Fig. 1 Abdominal CT scan showing the dilation of the pancreatic
main duct
Fig. 2 Endoscopic ultrasound showing a marked dilation of the
pancreatic main duct
Fig. 3 Pancreatic slide view of the collision tumor. The
morphological differences between the two types of tumors are
remarkable: NET on the upper left side and PDAC on the right
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frequent psammoma bodies. Reactions for gastrin, sero-
tonin, insulin, glucagon, calcitonin, and pancreatic poly-
peptide were negative. Ductal dysplasia and carcinoma in
situ, characterized by irregular epithelial budging and
bridging, small papillae, lack of fibro-vascular stalks, and
severe nuclear abnormalities, were detected in the pan-
creas and in the pancreatic main duct. Pathological exam-
ination of the jejunal lesion showed a fusiform type GIST,
CD117+ and CD34+, and wildtype for c-KIT/PDGFRA.
After surgery, the patient refused gemcitabine-based
adjuvant treatment. Currently, the patient has no signs
of relapse 8 months after surgery.
Discussion
We report the first case of a collision pancreatic tumor
constituted by a PDAC, without features of IPMNs, and
NET, associated with an incidental jejunal GIST. Pre-
operative work-up was consistent with malignant main-
duct IPMN, due to the dilation of the pancreatic main
duct (more than 2 cm), high serum Ca 19-9 levels, and
patient’s symptoms. Surprisingly, pathological examin-
ation showed an extensive adenocarcinoma that collided
with a neuroendocrine tumor involving the duodenum
and the head of the pancreas, with metastasis at the
peripancreatic and para-aortic nodes.
Collision tumors of the pancreas are rare; sporadic cases
of concomitant or collision tumors constituted by IPMNs
and NET [4–7], solid pseudopapillary neoplasm and NET
[8], and cancer of the bile duct and pancreas [9] have been
previously reported, but clinicopathological features and
prognosis of these tumors are substantially unclear. The
incidence of concomitant IPMNs and NETs has been re-
ported in a range from 2.6 to 4.6%, suggesting a non-
random association [10–12]. In most cases, the coexist-
ence of both tumors was an incidental discovery after the
examination of the surgical specimen. Two cases of a con-
comitant IPMN and a pancreatic NET diagnosed before
surgery have also been reported [13]. In 2013, Ishida et al.
[7] described a case of simultaneous IPMN and NET in
the pancreas and collected 15 previously reported cases.
Half of the patients were symptomatic (mainly abdominal
pain), only one patient presented with hormone-secreting
tumor, three patients had metastases from a NET, and one
patient died due to a metastatic NET. The origin of the
neoplastic population (common progenitor cell or random
association) has not been explained. Many authors sug-
gested that these tumors may arise from common precur-
sor stem cells [10, 14–16] as showed by a recent
molecular lineage study [17]. Others hypothesized that the
carcinogenesis of collision cancer may lead to alteration of
local immunodefence after the development of one tumor
or to the effect of a carcinogenic agent able to affect differ-
ent targets simultaneously [5]. Prognosis of collision ma-
lignant tumors is still unclear. In 2010, the largest
experience of collision cancers based on ten heteroge-
neous cases of pancreatic and periampullary cancers was
reported [5]. In this series, most collision cancers were
IPMNs coexisting with other malignancies (PDAC, NET,
lower end of common bile duct, and duodenal ampullary
carcinoma) and showed poor prognosis with a median
survival time of only 10 months.
Moriyoshi et al. [4] reported an interesting case of a
collision pancreatic tumor constituted by extensive
PanIN, coexisting with IPMNs with focal invasion and
multiple NETs in a patient affected by multiple endo-
crine neoplasia type 1. No lymph nodes metastases were
found; follow-up of the patient is not reported. Most of
NETs concomitant with exocrine neoplasms are non-
functioning tumors, but two cases of IPMNs and endo-
crine syndrome from nesidioblastosis (hypoglycemia)
and vipoma (watery diarrhea), respectively, have been re-
ported [18, 19].
Fig. 4 Immunohistochemical synaptophysin slide showing positive
neuroendocrine cells
Fig. 5 Immunohistochemical chromogranin A slide showing positive
neuroendocrine cells
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In our case, the presence of psammoma bodies could
suggest a somatostatin-producing NET; however, immuno-
histochemistry examination showed only a weak positivity
for somatostatin and negativity for gastrin, serotonin, and
pancreatic hormones. Moreover, the coexistence of a NET
and a GIST suggests a possible type 1 neurofibromatosis,
but the patient did not have clinical manifestations (such as
cutaneous and ocular) or familial history of the disease.
Differential diagnosis between mixed exocrine-endocrine
and collision tumors may arise. However, in the mixed type,
the exocrine-endocrine cells are closely combined [20]
while the collision type shows separate endocrine and exo-
crine components without an intermixed central zone [3],
as in our case.
Survival of patients with an extensive adenocarcinoma
and a malignant NET of the pancreas is obviously un-
known. Our patient refused adjuvant therapy, but she is
still alive and disease-free 8 months after surgery.
Conclusions
In conclusion, we report a new case of adenocarcinoma
coexisting with a metastatic NET of the pancreas, misin-
terpreted as a malignant IPMN. Intraoperative detection
of a jejunal GIST also occurred. Based on our case and re-
view of the literature, collision pancreatic cancer is a very
uncommon tumor composed at least of two different ma-
lignant components. Pathogenesis of this rare entity is
substantially unclear, and problems in differential diagno-
sis may arise between mixed exocrine-endocrine carcin-
oma or the collision of two distinct tumors. Preoperative
diagnosis is difficult because of the lack of specific symp-
toms and radiological features. Radical resection is still the
treatment of choice for resectable tumors, but the progno-
sis appears unpredictable.
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